HLA-B7 Inhibitors
HLA-B7 inhibitors encompass a spectrum of chemical compounds that indirectly attenuate the antigen-presenting function of HLA-B7 by targeting various intracellular processes essential for its activity. Flufenamic acid, for instance, reduces inflammation-driven upregulation of HLA-B7 by inhibiting cyclooxygenase, thereby decreasing prostaglandin levels and subsequent HLA-B7 expression. Chloroquine and Brefeldin A disrupt endosomal/lysosomal maturation and protein transport from the endoplasmic reticulum to the Golgi apparatus, respectively, leading to a reduced peptide pool for HLA-B7 presentation and impaired molecule maturation. Colchicine and Monensin further destabilize this process by interfering with microtubule polymerization and altering intracellular pH and ion concentrations, which are critical for the transport and proper assembly of HLA-B7. Leupeptin and E-64 specifically target proteases, diminishing the generation of antigenic peptides, while Nelfinavir and Lactacystin inhibit the proteasome, crucial for peptide generation for HLA-B7, culminating in an overall decrease in its antigen presentation capability.
The functionality of HLA-B7 is further compromised by inhibitors like Tunicamycin and Castanospermine, which prevent essential post-translational modifications and correct folding of the HLA-B7 molecules, leading to reduced surface expression and increased degradation of misfolded molecules. Cycloheximide, by inhibiting eukaryotic protein synthesis, indirectly reduces the overall production of HLA-B7, further contributing to a decline in its functional activity. These inhibitors collectively exert their influence through distinct biochemical pathways, yet converge on the common outcome of diminishing the HLA-B7 mediated immune response by hindering the presentation of antigenic peptides to T cells, a critical step for the initiation and regulation of adaptive immunity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $27.00 $79.00 $154.00 $309.00 | 1 | |
Flufenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) and also acts as a modulator of the immune response. By inhibiting the cyclooxygenase pathway, it can reduce the production of prostaglandins, which are involved in the inflammatory response. The decrease in prostaglandin levels can indirectly lead to a reduction in the presentation of antigens by HLA-B7, as inflammation is a key factor in the upregulation of MHC class I molecules. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is an antimalarial agent that has been shown to interfere with the maturation of endosomes and lysosomes. This can lead to a decrease in the degradation of internalized proteins, ultimately reducing the pool of peptides available for binding to HLA-B7 and subsequent presentation on the cell surface. This indirect mechanism impairs the functional activity of HLA-B7 in antigen presentation. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is an inhibitor of protein transport from the endoplasmic reticulum to the Golgi apparatus. By disrupting this transport, Brefeldin A can prevent the proper glycosylation and maturation of HLA-B7 molecules, which is crucial for their stability and surface expression, resulting in decreased functionality in antigen presentation. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine disrupts microtubule polymerization, a process essential for intracellular transport and secretion. The disruption of microtubules can affect the transport of HLA-B7 molecules to the cell surface, thereby reducing their ability to present antigens and signal to T cells. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that alters intracellular pH and ion concentrations. This can affect the protein folding and assembly of HLA-B7 in the endoplasmic reticulum, leading to a reduction in the availability of functional HLA-B7 molecules on the cell surface for antigen presentation. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin is a protease inhibitor that can inhibit the activity of lysosomal proteases. This can lead to a decrease in the generation of antigenic peptides that bind to HLA-B7, therefore decreasing the efficiency of antigen presentation by HLA-B7. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is another protease inhibitor that specifically inhibits cysteine proteases. By inhibiting these proteases, E-64 reduces the processing of antigens into peptides that can be loaded onto HLA-B7, resulting in reduced antigen presentation. | ||||||
Nelfinavir | 159989-64-7 | sc-507314 | 10 mg | $168.00 | ||
Nelfinavir is a protease inhibitor used in HIV therapy but can also inhibit the proteasome. The proteasome is responsible for generating peptides for MHC class I molecules such as HLA-B7. Inhibition of the proteasome by Nelfinavir results in a reduction of peptide supply for HLA-B7, impairing its antigen presentation function. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome, which plays a key role in the degradation of cytosolic proteins for antigen presentation by HLA-B7. By blocking the proteasome’s function, lactacystin reduces the availability of peptides for HLA-B7, thereby inhibiting its role in the immune response. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, a post-translational modification necessary for the stability and function of many proteins, including HLA-B7. This inhibition can result in misfolded HLA-B7 molecules that are degraded rather than presented on the cell surface, leading to decreased antigen presentation. | ||||||